Imatinib Completed Phase 2 Trials for Brain and Central Nervous System Tumors Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00039364Imatinib Mesylate in Treating Patients With Gliomas